上海摩漾生物科技有限公司获“C轮”融资，金额数亿人民币

Core Insights - Shanghai Moyang Biotechnology Co., Ltd. recently completed a Series C financing round, raising several hundred million RMB, with investors including Tianyi Capital, BlueRun Ventures, and Huagai Capital [1] Company Overview - Shanghai Moyang Biotechnology Co., Ltd. was established in 2018 and is located in Shanghai, primarily engaged in technology promotion and application services [1] - The company has a registered capital of 9.507324 million RMB and has completed its Series C financing by 2025, with the transaction amount being several hundred million RMB [1] Investment and Intellectual Property - The company has made investments in 6 external enterprises and holds 210 trademark registrations and 40 patents [1] - Additionally, it possesses 24 administrative licenses [1] Shareholders - The shareholders of Shanghai Moyang Biotechnology Co., Ltd. include Lin Guangming, Qingdao Maoda Venture Capital Partnership, Wuxi Qinfeng Xinyi Consulting Partnership, Hangzhou Huagai Qianning Equity Investment Partnership, and Shanghai Yangtze River Delta Industrial Upgrade Equity Investment Partnership [1]